Proteomic Innovation

“We are developing a novel blood test to PREDICT, at an EARLY point in pregnancy, a woman’s individual risk of having a premature baby. We aim to achieve our vision of improving the health of newborns by enabling earlier, effective interventions that make a difference.”  Dr. Greg Critchfield, CEO


Bill & Melinda Gates Foundation Has Agreed to Join Series B Financing

Sera Prognostics announced that the Bill & Melinda Gates Foundation has agreed to join the Company’s Series B financing, which will bring the total transaction to $25 million. Read More >

Sera Prognostics Closes $20 Million in Series B Financing

Sera Prognostics announced that it has closed $20 Million in Series B financing, led by Chione, Ltd, a European investment company, and appointed Mansoor Raza Mirza, M.D. to its Board of Directors. Read More >

Arnold L. Oronsky, Ph.D., Joins Sera’s Board of Directors

Sera Prognostics announced that Arnold L. Oronsky, Ph.D., General Partner at InterWest Partners, LLC, was appointed to its Board of Directors. Read More >

Our Goals

Providing AN Individualized Risk Assessment to Predict and Manage premature birth, preeclampsia, and other Pregnancy Complications

Sera Prognostics is focused on improving maternal and infant health by developing simple blood tests to predict the risks of pregnancy complications. Our initial focus is on one of the most serious pregnancy complications—preterm birth—which affects 11.4% of pregnancies in the U.S. alone.

Early and accurate prediction of risk for pregnancy complications may help pregnant women and their doctors take action and make a difference by putting early interventions in place. Learn about the PreTRM™ Test for Risk Management.